{"filings":[{"id":999922,"accession_number":"0001193125-26-267487","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2026-06-11T20:05:16+00:00","items":["5.07"],"status":"ready","headline":"Bolt Biotherapeutics reports 2026 annual meeting voting results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At June 10, 2026 annual meeting, 877,358 of 1,921,567 outstanding shares represented.","Directors William P. Quinn and Jakob Dupont elected as Class II members for three-year terms.","Quinn: 349,358 for, 52,117 withheld; Dupont: 377,163 for, 24,312 withheld; 475,883 broker non-votes each.","Ratification of PricewaterhouseCoopers as auditor for 2026: 768,336 for, 107,471 against, 1,551 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40201,"accession_number":"0001193125-26-219361","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2026-05-12T20:05:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics reports Q1 2026 results; cash $23.9M, BDC-4182 data expected Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Initial clinical data from BDC-4182 Phase 1/2 study for gastric/gastroesophageal cancer anticipated in Q3 2026.","Cash balance of $23.9M as of March 31, 2026; expected to fund operations into 2027, including dose-escalation completion.","Q1 2026 loss from operations $7.6M vs $12.1M in Q1 2025; R&D expense down to $4.8M from $9.5M.","Two next-generation ISAC programs (CEA and PD-L1) on hold pending BDC-4182 proof-of-concept.","Collaboration revenue fell to $26,000 in Q1 2026 from $1.2M in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":26000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106589,"accession_number":"0001193125-26-104102","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics reports FY2025 loss from ops $36.1M; cash $31.8M into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $7.7M for FY2025, flat YoY; Q4 2025 revenue $2.5M vs $0 in Q4 2024.","R&D expenses $28.5M in FY2025, down from $57.5M in FY2024; G&A $13.8M vs $18.5M, driven by restructuring.","Loss from operations $36.1M for FY2025 vs $73.0M in FY2024.","Cash, cash equivalents and marketable securities $31.8M as of Dec 31, 2025; expected to fund milestones into 2027.","Initial clinical data for BDC-4182 Phase 1 study (CLDN18.2) expected in Q3 2026; step-up dosing added to protocol."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122923,"accession_number":"0001193125-25-277521","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q3 2025: operating loss $7.7M, cash $38.8M; BDC-4182 data expected 3Q26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $2.2M (vs $1.1M Q3 2024); R&D expenses $6.5M (down 53% YoY).","Operating loss $7.7M vs $16.4M YoY, reflecting restructuring and discontinuation of BDC-1001.","Cash and securities $38.8M as of Sep 30, 2025; runway into 2027.","Initial Phase 1 data for BDC-4182 (claudin 18.2 ISAC) expected 3Q2026.","Presented preclinical data for next-gen CEA and PD-L1 ISACs at SITC; seeking partner for BDC-3042."],"consensus_eps_estimate":-5.9038,"consensus_eps_actual":-13.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":5195000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122922,"accession_number":"0001193125-25-228293","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["2.05","8.01"],"status":"ready","headline":"Bolt Biotherapeutics cuts workforce 50% and delays BDC-4182 data to Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduced by ~50% (approx. 20 employees); pre-tax charges $1.5-2.0M in Q4 2025.","Phase 1 study of BDC-4182 (claudin 18.2 ISAC) showing strong immune response; protocol modified for step-up dosing.","Initial clinical data for BDC-4182 now expected in Q3 2026, later than previously anticipated.","Cash runway extended into 2027 via restructuring and workforce reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139618,"accession_number":"0001641281-25-000006","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q2 2025 loss from ops $9.2M; cash $48.5M; BDC-4182 Phase 1 ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $1.8M (Q2 2024: $1.3M); R&D expenses down to $7.5M from $15.4M.","Loss from operations narrowed to $9.2M vs $22.6M year-over-year; restructuring charges zero vs $3.6M.","Cash, equivalents, and marketable securities $48.5M as of June 30, 2025; expected to fund operations through mid-2026.","Next-gen claudin 18.2 ISAC BDC-4182 Phase 1 dose-escalation open; initial data expected H1 2026.","Seeking partner for BDC-3042 after Phase 1 data; reverse stock split (1:20) done, regained Nasdaq compliance."],"consensus_eps_estimate":-6.579,"consensus_eps_actual":-10.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":3026000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157199,"accession_number":"0000950170-25-083180","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Bolt Biotherapeutics effects 1-for-20 reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-20 ratio effective June 6, 2025.","Common stock begins trading on split-adjusted basis June 9, 2025 on Nasdaq under ticker BOLT.","New CUSIP number is 097702203; par value unchanged at $0.00001 per share.","No fractional shares issued; cash payment in lieu of fractional shares.","Proportionate adjustments to outstanding stock options, equity plans, and warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157198,"accession_number":"0000950170-25-081607","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bolt Biotherapeutics announces 1-for-20 reverse stock split effective June 6, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio 1:20 approved by board on May 27, 2025.","Effective at 5:00pm ET on June 6, 2025; trading starts split-adjusted June 9.","Ticker remains BOLT on Nasdaq Capital Market; new CUSIP 097702203.","No fractional shares issued; cash paid in lieu of fractional shares.","Par value unchanged at $0.00001; all shares and equity awards adjusted proportionally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157197,"accession_number":"0000950170-25-077880","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bolt Biotherapeutics stockholders approve reverse stock split amendment at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split amendment approved: 20,983,236 votes for, 3,224,611 against (86.9% of votes cast).","Laura Berner and Brian O'Callaghan elected as Class I directors with 10.6M and 11.2M votes for, respectively.","PricewaterhouseCoopers LLP ratified as independent auditor for FY2025: 23,330,316 votes for.","Annual meeting had 24,362,318 shares represented out of 38,339,697 entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157196,"accession_number":"0000950170-25-069153","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q1 2025: operating loss $12.1M; cash $58M; BDC-4182 Phase 1 open","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $1.2M (down from $5.3M in Q1 2024) due to completion of Innovent agreement.","R&D expense $9.5M (down from $16.5M); G&A $3.8M (down from $5.8M) reflecting May 2024 restructuring.","Cash balance $58.0M expected to fund operations and milestones through mid-2026.","BDC-4182 Phase 1 dose-escalation study for gastric/gastroesophageal cancer opened for enrollment in April 2025.","Partnering process initiated for BDC-3042 after AACR 2025 data showed favorable safety and biological activity."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":1222000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157195,"accession_number":"0000950170-25-054871","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Bolt Biotherapeutics amends bylaws to reduce stockholder quorum to one-third of shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended bylaws on April 15, 2025, effective immediately.","Quorum requirement lowered from majority to one-third of outstanding voting shares.","Change applies to all stockholder meetings and separate class votes unless otherwise required.","No changes to fiscal year or other governance provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175544,"accession_number":"0000950170-25-043869","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q4 2024 loss from ops $16.9M; cash $70.2M; BDC-4182 starts trial Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 2024 loss from operations $16.9M vs $19.8M in Q4 2023; full-year loss $73.0M vs $76.2M.","Collaboration revenue Q4 $7.7M (up from $2.1M Q4 2023); full year $7.7M (down from $7.9M).","Cash $70.2M expected to fund key milestones and operations through mid-2026.","BDC-4182 on track to start Phase 1 trial in gastric cancer in Q2 2025.","BDC-3042 Phase 1 fully enrolled at highest dose; no DLTs; data update expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175543,"accession_number":"0000950170-25-001159","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bolt Biotherapeutics transfers to Nasdaq Capital Market to extend bid price compliance deadline to June 30, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Transfer approved Jan 2, 2025; effective at market open Jan 6, 2025.","Company failed to regain $1 minimum bid price by original Dec 30, 2024 deadline.","Additional compliance period until June 30, 2025; must close at $1+ for 10 consecutive business days.","Bolt may effect a reverse stock split to cure the deficiency if needed.","Failure to regain compliance by June 30 could lead to delisting and a potential Nasdaq appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192498,"accession_number":"0000950170-24-139580","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Mahendra Shah resigns from Bolt Biotherapeutics board; Dupont added to two committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Mahendra Shah notified his resignation on Dec 19, effective Dec 31, 2024, for personal reasons.","Shah's departure not due to any disagreement with the company's operations, policies, or practices.","Board appointed existing director Dr. Jakob Dupont to the Audit Committee and Nominating and Corporate Governance Committee, effective upon Shah's resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192497,"accession_number":"0000950170-24-125376","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q3 2024: cash $84.4M; BDC-3042 advances to 10 mg/kg cohort","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $84.4M as of Sept 30, 2024; expected to fund operations through mid-2026.","Q3 operating loss $16.4M vs $18.2M in Q3 2023; R&D expenses $13.8M, G&A $3.8M.","BDC-3042 Phase 1 advanced to 10 mg/kg cohort; data update expected H1 2025.","BDC-4182 on track for clinical trial start in Q2 2025; preclinical data at SITC.","Collaboration revenue $1.1M, down from $2.5M in prior-year quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":7690000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208968,"accession_number":"0001193125-24-213225","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bolt Biotherapeutics appoints Dr. Jakob Dupont to Board; two directors resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Healy, M.D., Ph.D., resigned from Board effective Sept 3, 2024; no disagreement with company.","Frank D. Lee also resigned from Board effective Sept 3, 2024; no disagreement with company.","Board appointed Jakob Dupont, M.D., Ph.D., as Class II director effective Sept 3, 2024.","Dr. Dupont is Executive Venture Partner at Sofinnova Investments; former Global Head of R&D at Atara Bio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208967,"accession_number":"0000950170-24-096191","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q2 2024 loss from operations $22.6M; cash $97.5M, BDC-3042 advances to Cohort 6","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Loss from operations of $22.6M for Q2 2024 vs $19.8M in Q2 2023; restructuring charges of $3.6M.","Cash, cash equivalents and marketable securities of $97.5M as of June 30, 2024; runway through mid-2026.","BDC-3042 Phase 1 advanced to Cohort 6; no dose-limiting toxicities in Cohort 5.","BDC-4182 (claudin 18.2-targeting ISAC) abstract accepted at SITC 2024; IND-enabling activities ongoing.","Collaboration revenue $1.3M; R&D expenses $15.4M; G&A expenses $4.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":6549000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208966,"accession_number":"0001193125-24-175113","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bolt Biotherapeutics receives Nasdaq bid price deficiency notice; 180 days to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Avg closing price of common stock fell below $1.00 over prior 30 trading days as of July 1, 2024.","180-day grace period until Dec 30, 2024 to regain compliance by closing at $1.00+ for 10 consecutive business days.","If not compliant, may qualify for an additional 180-day extension if other listing standards met.","Company intends to monitor bid price and evaluate options including potential reverse stock split.","Notice has no immediate effect on listing; stock continues trading on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226795,"accession_number":"0000950170-24-073501","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bolt Biotherapeutics annual meeting elects directors and ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Director Kathleen LaPorte elected with 12,706,287 votes for, 3,990,176 withheld, 9,231,722 broker non-votes.","Director Nicole Onetto elected with 12,819,050 votes for, 3,880,294 withheld, 9,228,841 broker non-votes.","Ratification of PricewaterhouseCoopers LLP as auditor for FY2024: 23,736,566 for, 2,032,686 against, 158,933 abstaining.","Total shares represented at meeting: 25,928,185 of 38,127,740 shares entitled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226794,"accession_number":"0000950170-24-059524","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","2.05","5.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics restructures, cuts 50% workforce, CEO replaced; Q1 loss $17.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 2024: loss from ops $17.1M; collaboration revenue $5.3M; cash $112.8M.","Discontinuing trastuzumab imbotolimod (BDC-1001); focusing on BDC-3042 and next-gen ISAC BDC-4182 targeting Claudin 18.2.","Reducing workforce by ~50% (50 employees); estimated pre-tax charges $3-4M for severance and related costs.","CEO Randall Schatzman steps down; CFO Willie Quinn appointed President & CEO; CMO Edith Perez also departs; new COO Grant Yonehiro named.","Cash runway extended into H2 2026, funding completion of BDC-3042 Phase 1 and clinical data for BDC-4182."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245752,"accession_number":"0000950170-24-034688","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics reports Q4/FY2023 results; cash $128.6M funds through late 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities at $128.6M as of Dec 31, 2023; expected to fund through late 2025.","Collaboration revenue $2.1M in Q4 and $7.9M for FY2023, up from $1.4M and $5.7M prior year.","Loss from operations improved to $19.8M (Q4) and $76.2M (FY2023) vs $21.0M and $90.3M.","BDC-1001 Phase 2 advancing in five HER2-positive tumor cohorts; 29% ORR at RP2D reported at ESMO 2023.","BDC-3042 Phase 1 cleared three dose levels without DLT; now enrolling fourth cohort."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263221,"accession_number":"0000950170-23-062027","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q3 2023: cash $141.4M, BDC-1001 29% ORR, BDC-3042 dosed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $141.4M as of Sept 30, 2023; expected to fund operations through 2025.","Collaboration revenue $2.5M (vs $2.1M Q3 2022); R&D expenses $15.0M (down from $19.0M).","Loss from operations of $18.2M vs $22.3M in prior year quarter.","BDC-1001 Phase 1 updated data: 29% ORR monotherapy; first complete response; well tolerated; Orphan Drug Designation for gastric cancers.","First patient dosed with BDC-3042 in Phase 1/2 for advanced solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":5787000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280409,"accession_number":"0000950170-23-039047","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q2 2023 cash $157.1M, initiates BDC-1001 Phase 2, gets IND for BDC-3042","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $157.1M as of June 30, 2023; runway expected through 2025.","First patients dosed in BDC-1001 Phase 2 dose-expansion study for HER2+ colorectal, endometrial, and gastroesophageal cancers.","FDA cleared IND for BDC-3042 (Dectin-2 agonist) in July 2023; Phase 1 start expected later in 2023.","Loss from operations $19.8M in Q2 2023 vs $23.1M in Q2 2022; R&D expenses reduced to $15.6M from $18.9M.","Collaboration revenue flat at $1.4M; G&A essentially unchanged at $5.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":3259000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298964,"accession_number":"0000950170-23-027743","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bolt Biotherapeutics annual meeting elects three directors, ratifies PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Randall C. Schatzman, Ph.D. elected with 18,339,155 votes for, 49,830 withheld.","Edgar G. Engleman, M.D. elected with 18,300,413 votes for, 88,572 withheld.","James I. Healy, M.D., Ph.D. elected with 14,449,941 votes for, 3,939,044 withheld.","Ratification of PricewaterhouseCoopers LLP as auditor for FY2023: 26,831,426 for, 33,439 against, 15,578 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298963,"accession_number":"0000950170-23-021225","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q1 2023 net loss $18.4M; cash $171M; BDC-1001 Phase 2 plans","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from operations $18.4M vs $23.9M in Q1 2022; collaboration revenue $1.8M (up from $0.8M).","Cash, equivalents, and marketable securities $171.0M as of March 31, 2023; expected to fund operations through 2025.","R&D expenses $14.6M (down from $18.4M) due to lower manufacturing and pipeline reprioritization.","BDC-1001 Phase 2 program to initiate in 2023 in HER2+ colorectal, endometrial, gastroesophageal, and breast cancer.","Comprehensive BDC-1001 safety/efficacy data to be presented at ASCO 2023 on June 3."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":1826000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319136,"accession_number":"0000950170-23-010609","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bolt Biotherapeutics reports positive BDC-1001 Phase 1 data; advances to Phase 2; cash $192.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BDC-1001 elicited objective responses including partial responses and stable disease across multiple HER2+ solid tumors as monotherapy and with nivolumab.","Phase 2 program to start in 2023: two studies in breast, colorectal, endometrial, and gastroesophageal cancers.","Entered clinical supply agreement with Roche for pertuzumab (Perjeta) to combine with BDC-1001 in breast cancer.","Cash, cash equivalents, and marketable securities of $192.8M as of Dec 31, 2022, expected to fund operations through 2025.","Full-year 2022 collaboration revenue $5.7M; R&D expenses $73.1M; loss from operations $90.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337362,"accession_number":"0000950170-22-026551","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bolt Biotherapeutics appoints Laura Berner to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10; Laura Berner appointed as Class I director, term through 2025 annual meeting.","Berner qualifies as independent under Nasdaq rules; no reportable related-party transactions.","Received initial option award for 50,000 shares, vesting over 36 months, and prorated option for 12,261 shares.","Eligible for annual option of 25,000 shares and $35,000 cash retainer under non-employee director compensation policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337361,"accession_number":"0000950170-22-024476","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q3 2022 operating loss $22.3M; cash $209.6M funds through 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $209.6M as of Sep 30, 2022; expected to fund operations and milestones through 2025.","BDC-1001 dose-escalation trial on track to complete enrollment by year-end; topline data and RP2D expected Q1 2023.","BDC-3042 IND-enabling progressing; on track for clinical entry in 2023.","Collaboration revenue $2.1M (up from $0.8M YoY); R&D expense $19.0M, G&A $5.5M.","Loss from operations $22.3M vs $23.5M in Q3 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":4318000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354729,"accession_number":"0000950170-22-016454","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q2 loss $23.1M; cash $223.6M extends runway to 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $1.4M vs $0 in Q2 2021; R&D spend $18.9M, G&A $5.5M.","Cash and securities $223.6M as of June 30, extended cash runway through 2025 via portfolio prioritization.","BDC-1001 monotherapy/combination dose-escalation data and RP2D expected H2 2022.","BDC-2034 discontinued due to off-target toxicity; focus on BDC-1001, BDC-3042, and next-gen ISAC.","BDC-3042 IND-enabling studies underway; clinical start on track for 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":2206000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372729,"accession_number":"0000950170-22-011505","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders elect three Class I directors and ratify PwC as auditor for FY2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Frank D. Lee (23,819,385 votes for), Brian O'Callaghan (22,559,100), Mahendra G. Shah (19,746,587) elected to Board.","Ratification of PricewaterhouseCoopers LLP as auditor for fiscal 2022 passed with 27,023,546 for, 73,833 against, 6,030 abstentions.","Broker non-votes totaled 3,142,984 on director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372728,"accession_number":"0000950170-22-009651","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q1 2022: Cash $246.8M; BDC-1001 data on track for H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Cash, cash equivalents and marketable securities $246.8M at March 31, 2022; expected to fund operations into 2024.","Collaboration revenue $0.8M from Genmab and Innovent partnerships; R&D expenses $18.4M vs $14.1M prior year.","Loss from operations $23.9M vs $18.4M in Q1 2021, reflecting increased clinical and IND-enabling activities.","Lead ISAC BDC-1001 monotherapy and OPDIVO combo dose escalation on track; data readout expected H2 2022.","IND-enabling activities for CEA-targeted BDC-2034 and Dectin-2 agonist BDC-3042 progressing; BDC-3042 clinical start planned 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":813000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391553,"accession_number":"0000950170-22-005040","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2022-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics reports 2021 results; cash $271.6M, BDC-1001 on track for RP2D in 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities $271.6M at Dec 31, 2021 vs $22.8M at end 2020; runway into 2024.","Collaboration revenue $1.3M for FY 2021 from Genmab R&D collaboration (vs $0.2M in 2020).","R&D expenses $75.7M, G&A $18.4M; operating loss $92.8M for FY 2021.","BDC-1001 (HER2) Phase 1/2 on track for recommended Phase 2 dose in 2022; Opdivo combo arm dosed first patient Dec 2021.","Preclinical data on BDC-2034, BDC-3042, and PD-L1 ISAC to be presented at AACR 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391552,"accession_number":"0000950170-22-002873","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2022-03-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics CSO David Dornan resigns, stays as consultant for 6 months","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Dornan, Ph.D. resigned as Chief Scientific Officer effective March 11, 2022.","Entered consulting agreement for 6 months at $500/hour to assist transition.","Outstanding equity awards will continue to vest during consulting period.","Consultant reports to CEO Randall Schatzman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391551,"accession_number":"0001564590-22-002321","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2022-01-25T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Bolt Biotherapeutics amends supply agreement with EirGenix for trastuzumab biosimilar; up to $2M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended supply agreement with EirGenix for bulk drug substance EG12014, a trastuzumab biosimilar used in BDC-1001 HER2 Boltbody ISAC.","Requires joint steering committee, revised forecasting/order terms, and pricing adjustments based on production scale.","Company to make up to $2.0M in milestone payments upon regulatory achievements for HER2 Boltbody ISAC.","Agreement remains effective as long as Bolt or affiliates continue development/commercialization of the ISAC product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409764,"accession_number":"0001564590-21-060502","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2021-12-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bolt Biotherapeutics appoints Nicole Onetto to board; Ashish Khanna resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ashish Khanna resigned from Bolt board and its Audit and Compensation committees effective Dec 13, 2021; no disagreement.","Nicole Onetto appointed as Class III director effective Dec 14, 2021; term expires at 2024 annual meeting.","Dr. Onetto received initial option grant of 27,860 shares vesting over 36 months and annual grant of 13,930 shares.","She also receives $35,000 annual cash retainer and standard indemnification; Board determined she is independent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409763,"accession_number":"0001564590-21-059379","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2021-12-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bolt Biotherapeutics reports interim Phase 1/2 BDC-1001 data: safe, 1 durable PR at 52 weeks, no CRS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BDC-1001 showed favorable safety in 57 patients; no dose-limiting toxicities up to 20 mg/kg Q3W and 12 mg/kg Q2W.","One durable partial response maintained through 52 weeks; multiple patients with stable disease >12 weeks in 40 evaluable subjects.","No cytokine release syndrome (CRS) observed; maximum tolerated dose not yet reached.","Plasma/tissue biomarkers confirm TLR7/8 activation and myeloid cell infiltration consistent with mechanism of action.","Company plans to continue monotherapy dose escalation, evaluate weekly dosing, and initiate combination with nivolumab by year-end 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409762,"accession_number":"0001564590-21-057696","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2021-11-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bolt Biotherapeutics appoints two new directors and lead independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Peter Moldt resigned from Board and Compensation Committee; no disagreement.","Board expanded from 8 to 9; appointed Brian O'Callaghan and Frank Lee as Class I directors.","O'Callaghan named chair of Compensation Committee; Lee joins Nominating and Corporate Governance Committee.","Each new director received initial option for 27,860 shares, annual option for 13,930 shares, and cash retainers.","Existing director Jim Healy appointed as lead independent director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409761,"accession_number":"0001564590-21-055698","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q3 2021: cash $290.5M; BDC-1001 interim data at ESMO I-O in Dec","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $290.5M at Sep 30, 2021; plus $5M upfront from Innovent in Oct.","Operating loss $23.5M in Q3 2021 vs $12.4M in Q3 2020; R&D expenses rose to $19.3M.","BDC-1001 Phase 1/2 monotherapy interim data (>50 patients) to be presented at ESMO I-O Congress in Dec 2021.","Combination dose escalation with Opdivo expected to start Q4 2021; collaboration with Innovent for up to 3 ISACs.","Cash expected to fund operations through end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":752000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428657,"accession_number":"0001564590-21-043969","cik":1641281,"company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bolt Biotherapeutics Q2 cash $310.9M; R&D spend doubles; Genmab collaboration on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities of $310.9M as of June 30, 2021, expected to fund operations through end of 2023.","R&D expenses $19.7M vs $9.2M YoY; G&A expenses $4.1M vs $2.0M YoY; loss from operations $23.8M vs $11.1M YoY.","Lead program BDC-1001 Phase 1/2 data update expected in 2H 2021; Phase 2 monotherapy and combo dose-escalation to initiate in 2H 2021.","Announced R&D collaboration with Genmab for bispecific ISACs: $10M upfront + $15M equity investment; Genmab fully funds three programs through initial proof-of-concept.","Expanded leadership: added VPs in Clinical Development, Early Development, Biometrics, Program Management, HR, and Communications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10184304.503311258,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}